CTLA4 and neoplasm: However, in preclinical studies of melanoma, combined targeting of CTLA-4 and PD-1 more than doubled the rate of tumor rejection and increased tumor-infiltrating T-cells while reducing Tregs and MDSCs in the TME [82].